{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:37:34Z","timestamp":1792553854620,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes of relapsed and\/or refractory large B-cell lymphoma (r\/r LBCL). However, its off-tumor effects result in severe prolonged humoral immune deficiency. Cytomegalovirus (CMV) is a latent virus that can be life-threatening in immunosuppressed patients. In the setting of CAR T-cell therapy, Asian race is a risk factor for clinically significant CMV infection. However, the effect of CAR T-cell therapy on CMV reactivation in Japanese patients remains unclear. Previous reports used polymerase chain reaction (PCR), but we used the pp65 antigenemia assay to retrospectively investigate long-term effects in patients with r\/r LBCL. The study included 46 patients. Nine (19.6%) developed CMV reactivation, with a median onset of 13\u00a0days. Six of these patients received preemptive therapy, and none developed CMV end-organ disease. Primary refractory disease, grade 2\u20134 cytokine release syndrome, and high-dose corticosteroids were risk factors for CMV reactivation. Long-term follow-up showed that CMV reactivation rarely occurred later than 28\u00a0days post-infusion. Our study using the pp65 antigenemia assay showed a similar incidence of CMV reactivation, onset, and risk factors to those in the previous reports using PCR.<\/jats:p>","DOI":"10.1007\/s12185-025-04023-y","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T10:58:05Z","timestamp":1750157885000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy"],"prefix":"10.1007","volume":"122","author":[{"given":"Kenta","family":"Hayashino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-0265","authenticated-orcid":false,"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Masunari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"4023_CR1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","volume":"19","author":"O Bupha-Intr","year":"2021","unstructured":"Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther. 2021;19:749\u201358.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4023_CR2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136:925\u201335.","journal-title":"Blood"},{"key":"4023_CR3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67:533\u201340.","journal-title":"Clin Infect Dis"},{"key":"4023_CR4","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis. 2020;7:ofaa121.","journal-title":"Open Forum Infect Dis"},{"key":"4023_CR5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L, Zhou X, Jin J, Li C, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer. 2019;7:271.","journal-title":"J Immunother Cancer"},{"key":"4023_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","volume":"20","author":"MJ Cannon","year":"2010","unstructured":"Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202\u201313.","journal-title":"Rev Med Virol"},{"key":"4023_CR7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","volume":"34","author":"P Ljungman","year":"2002","unstructured":"Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094\u20137.","journal-title":"Clin Infect Dis"},{"key":"4023_CR8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619\u201329.","journal-title":"Blood"},{"key":"4023_CR9","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"4023_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hon.2453","volume":"36","author":"F Marchesi","year":"2018","unstructured":"Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol. 2018;36:381\u201391.","journal-title":"Hematol Oncol"},{"key":"4023_CR11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3109\/10428194.2012.739285","volume":"54","author":"T Hosoda","year":"2013","unstructured":"Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013;54:1327\u20138.","journal-title":"Leuk Lymphoma"},{"key":"4023_CR12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1515\/med-2021-0274","volume":"16","author":"L Pezzullo","year":"2021","unstructured":"Pezzullo L, Giudice V, Serio B, Fontana R, Guariglia R, Martorelli MC, et al. Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars). 2021;16:672\u201382.","journal-title":"Open Med (Wars)"},{"key":"4023_CR13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","volume":"48","author":"S Aksoy","year":"2007","unstructured":"Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307\u201312.","journal-title":"Leuk Lymphoma"},{"key":"4023_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jcv.2012.10.001","volume":"56","author":"L Cardenoso","year":"2013","unstructured":"Cardenoso L, Pinsky BA, Lautenschlager I, Aslam S, Cobb B, Vilchez RA, et al. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. J Clin Virol. 2013;56:108\u201312.","journal-title":"J Clin Virol"},{"key":"4023_CR15","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260\u201372.","journal-title":"Lancet Infect Dis"},{"key":"4023_CR16","doi-asserted-by":"crossref","first-page":"ofaa422","DOI":"10.1093\/ofid\/ofae422","volume":"11","author":"F Khawaja","year":"2024","unstructured":"Khawaja F, Ahmed S, Iyer SP, Sassine J, Handley G, Prakash R, et al. Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes. Open Forum Infect Dis. 2024;11:ofaa422.","journal-title":"Open Forum Infect Dis"},{"key":"4023_CR17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2023","unstructured":"Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108:615\u201320.","journal-title":"Haematologica"},{"key":"4023_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","volume":"108","author":"O Beyar-Katz","year":"2022","unstructured":"Beyar-Katz O, Kikozashvili N, Bar On Y, Amit O, Perry C, Avivi I, et al. Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. Eur J Haematol. 2022;108:52\u201360.","journal-title":"Eur J Haematol"},{"key":"4023_CR19","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","volume":"8","author":"RY Lin","year":"2024","unstructured":"Lin RY, Anderson AD, Natori Y, Raja M, Morris MI, Jimenez AJ, et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024;8:3813\u201322.","journal-title":"Blood Adv"},{"key":"4023_CR20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","volume":"78","author":"E Kampouri","year":"2024","unstructured":"Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, et al. Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin Infect Dis. 2024;78:1022\u201332.","journal-title":"Clin Infect Dis"},{"issue":"851","key":"4023_CR21","first-page":"e1","volume":"28","author":"E Marquez-Algaba","year":"2022","unstructured":"Marquez-Algaba E, Iacoboni G, Pernas B, Esperalba J, Los Arcos I, Navarro V, et al. Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2022;28(851):e1\u20138.","journal-title":"Transplant Cell Ther"},{"key":"4023_CR22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s13337-021-00728-w","volume":"32","author":"S Karami","year":"2021","unstructured":"Karami S, Roshandel E, Ghaffari Nazari H, Hajifathali A, Tavakoli F, Parkhideh S. In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients. Virusdisease. 2021;32:422\u201334.","journal-title":"Virusdisease"},{"key":"4023_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bmt.1704369","volume":"33","author":"T Mori","year":"2004","unstructured":"Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"4023_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","volume":"5","author":"JH Baird","year":"2021","unstructured":"Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021;5:143\u201355.","journal-title":"Blood Adv"},{"key":"4023_CR25","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock S, B\u00fccklein VL, Blumenberg V, Magno G, Emhardt AJ, Holzem AME, et al. Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. Hemasphere. 2025;9: e70062.","journal-title":"Hemasphere"},{"key":"4023_CR26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"4023_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87\u201391.","journal-title":"Clin Infect Dis"},{"key":"4023_CR28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4023_CR29","unstructured":"Schimmer BP. Adrenocorticotropic Hormone, Adrenal Steroids, and the Adrenal Cortex. The Pharmacological Basis of Therapeutics, 13e. McGraw-Hill Education. 2017."},{"key":"4023_CR30","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513.","journal-title":"Blood"},{"key":"4023_CR31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"4023_CR32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4023_CR33","doi-asserted-by":"crossref","unstructured":"Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK et al. CMV reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin Infect Dis. 2024;8:1022\u20131032.","DOI":"10.1093\/cid\/ciad708"},{"key":"4023_CR34","doi-asserted-by":"publisher","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH et al. Recommendations from the 10th European conference on infections in leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S1473-3099(25)00069-6","DOI":"10.1016\/S1473-3099(25)00069-6"},{"key":"4023_CR35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1086\/339963","volume":"185","author":"N Khan","year":"2002","unstructured":"Khan N, Cobbold M, Keenan R, Moss PA. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis. 2002;185:1025\u201334.","journal-title":"J Infect Dis"},{"key":"4023_CR36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2003-03-0824","volume":"103","author":"E Kondo","year":"2004","unstructured":"Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004;103:630\u20138.","journal-title":"Blood"},{"key":"4023_CR37","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.21037\/apm-20-1352","volume":"9","author":"M Zhao","year":"2020","unstructured":"Zhao M, Zhuo C, Li Q, Liu L. Cytomegalovirus (CMV) infection in HIV\/AIDS patients and diagnostic values of CMV-DNA detection across different sample types. Ann Palliat Med. 2020;9:2710\u20135.","journal-title":"Ann Palliat Med"},{"key":"4023_CR38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinte.1995.00430140115012","volume":"155","author":"DL Hanson","year":"1995","unstructured":"Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med. 1995;155:1537\u201342.","journal-title":"Arch Intern Med"},{"key":"4023_CR39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.aat0066","volume":"363","author":"JP Martins","year":"2019","unstructured":"Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, et al. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. Science. 2019;363:288\u201393.","journal-title":"Science"},{"key":"4023_CR40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiz192","volume":"220","author":"FM Saccoccio","year":"2019","unstructured":"Saccoccio FM, Jenks JA, Itell HL, Li SH, Berry M, Pollara J, et al. Humoral immune correlates for prevention of postnatal cytomegalovirus acquisition. J Infect Dis. 2019;220:772\u201380.","journal-title":"J Infect Dis"},{"key":"4023_CR41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","volume":"27","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27:770\u201381.","journal-title":"J Clin Oncol"},{"key":"4023_CR42","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1002\/jmv.27257","volume":"93","author":"E Cousin","year":"2021","unstructured":"Cousin E, Belicard F, Michel L, Pronier C, Lassalle N, Lamy T, et al. Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: a rare but potentially fatal complication. J Med Virol. 2021;93:6398\u2013403.","journal-title":"J Med Virol"},{"key":"4023_CR43","doi-asserted-by":"crossref","first-page":"1226148","DOI":"10.3389\/fimmu.2023.1226148","volume":"14","author":"J Cheng","year":"2023","unstructured":"Cheng J, Huang J, Cao W, Huang L, Mao X, Chen L, et al. Case report: fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. Front Immunol. 2023;14:1226148.","journal-title":"Front Immunol"},{"key":"4023_CR44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/curroncol29020044","volume":"29","author":"C Zu","year":"2022","unstructured":"Zu C, Xu Y, Wang Y, Zhang M, Zhao H, Fang X, et al. Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma. Curr Oncol. 2022;29:490\u20136.","journal-title":"Curr Oncol"},{"key":"4023_CR45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16623","volume":"191","author":"J Wang","year":"2020","unstructured":"Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020;191:212\u201322.","journal-title":"Br J Haematol"},{"key":"4023_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","volume":"25","author":"P Ljungman","year":"2011","unstructured":"Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151\u201369.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4023_CR47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2165\/00003495-200161080-00013","volume":"61","author":"M Curran","year":"2001","unstructured":"Curran M, Noble S. Valganciclovir. Drugs. 2001;61:1145\u201350 (discussion 51\u20132).","journal-title":"Drugs"},{"key":"4023_CR48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"4023_CR49","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1182\/blood.V80.5.1358.1358","volume":"80","author":"M Boeckh","year":"1992","unstructured":"Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80:1358\u201364.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04023-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:37:16Z","timestamp":1761770236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04023-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4023"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04023-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.M. has received honoraria from Bristol Myers Squibb. D.E., N.F., and Y.M. have received honoraria from Novartis, Bristol Myers Squibb, Gilead Sciences, and Janssen Pharmaceutical. K.F. has received honoraria from Bristol Myers Squibb and Gilead Sciences. The others have no conflict of interest for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board (#2405-051).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is a retrospective observational study and obtaining written consent was not mandatory. All participants did not provide any denial to this study documents that were made available to them on an opt-out manner on the Web. The opt-out method was approved by the institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}